Radiobiology and Clinical Application of Halogenated Pyrimidine Radiosensitizers

References

• Atcher R.W., Russo A., Degraff W.G., Moore M., Grdina D.J., Mitchell J.B. Halogenated pyrimidines as radiosensitizers for high-LET radiation. Radiation Research 1989; 117: 351–355
   PubMed Web of Science ®Google Scholar
• Bagshaw M.A., Doggett R.L.S., Smith K.C., Kaplan H.S., Nelsen T.S. Intra-arterial 5-bromodeoxyuridine and X ray therapy. American Journal of Roentgenology 1967; 99: 886–894
   Web of Science ®Google Scholar
• Collins J.M., Dedrick R.L., King F.G., Speyer J.L., Myers C.E. Nonlinear pharmacokinetic models for 5-flurouracil in man: intravenous and intra-peritoneal routes. Clinical Pharmacology and Therapy 1980; 28: 235–246
   PubMed Web of Science ®Google Scholar
• Dickson R.B., McManaway M.E., Lippman M.E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986; 232: 1540–1543
   PubMed Web of Science ®Google Scholar
• Djordjevic B., Szybalski W. Genetics of human cell lines. III. Incorporation of 5-bromo and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. Journal of Experimental Medicine 1960; 112: 509–531
   PubMed Web of Science ®Google Scholar
• Ensminger W.D., Gyves J.W. Regional cancer chemotherapy. Cancer Treatment Reports 1984; 68: 101–115
   PubMedGoogle Scholar
• Erikson R.L., Szybalski W. Molecular radiobiology of human cell lines. V. Comparative radiosensitizing properties of 5-halodeoxycytidines and 5-halodeoxyuridines. Radiation Research 1963; 20: 252–262
   PubMed Web of Science ®Google Scholar
• Giusti G., Mangon C., Petrocellis B., Scarano E. Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic human tissue. Enzyme Biology Clin. 1970; 11: 375–383
   PubMedGoogle Scholar
• Greenberg, H.S., Chandler, W.F., Diaz, R.F., et al. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. Journal of Neurosurgery 1988; 69: 500–505
   PubMed Web of Science ®Google Scholar
• Greer S. Studies on ultraviolet irradiation of Escherichia coli containing 5-bromouracil in its DNA. Journal of General Microbiology 1960; 22: 618–634
   PubMedGoogle Scholar
• Hoshino T., Sano K. Radiosensitization of malignant brain tumors with bromouridine (thymidine analogue). Acta Radiologica 1969; 8: 15–26
   Web of Science ®Google Scholar
• Hoshino T., Nagashima T., Cho K.G., Murovic J.A., HOdes J.E., Wilson C.B., Edwards M.S.B., Pitts L.H. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. International Journal of Cancer 1986; 38: 369–374
   PubMed Web of Science ®Google Scholar
• Hug V., Johnston D., Finders M., Hortobagyi G. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Research 1986; 46: 147–152
   PubMed Web of Science ®Google Scholar
• Iliakis G., Kurtzman S. Application of non-hypoxic cell sensitizers in radiobiology and radiotherapy: rationale and future prospects. International Journal of Radiation Oncology, Biology, and Physics 1989; 16: 1235–1241
   PubMed Web of Science ®Google Scholar
• Jackson D., Kinsella T., Rowland J., Wright D., Katz D., Main D., Collins J., Kornblith P., Glatstein E. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. American Journal of Clinical Oncology (CCT) 1987; 10: 437–443
   PubMed Web of Science ®Google Scholar
• Kinsella T.J., Mitchell J.B., Russo A., Aiken M., Morstyn G., Hsu S.M., Rowland J., Glatstein E. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. Journal of Clinical Oncology 1984; 2: 1144–1150
   PubMed Web of Science ®Google Scholar
• Kinsella T.J., Russo A., Mitchell J.B., Collins J.M., Rowland J., Wright D., Glatstein E. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. International Journal of Radiation Oncology, Biology, and Physics 1985; 11: 1941–1946
   PubMed Web of Science ®Google Scholar
• Kinsella T.J., Dobson P.P., Mitchell J.B., Fornace A.J.J. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. International Journal of Radiation Oncology, Biology, and Physics 1987; 13: 733–739
   PubMed Web of Science ®Google Scholar
• Kinsella T.J., Glatstein E. Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer 1987; 59: 908–915
   PubMed Web of Science ®Google Scholar
• Klecker R.W., Jenkins J.F., Kinsella T.J., Fine R.L., Strong J.M., Collins J.M. Clinical pharmacology of 5-iodo-2-deoxyuridine and 5-iodouracil, and endogenous pyrimidine modulation. Clinical Pharmacology and Therapy 1985; 38: 45–51
   PubMed Web of Science ®Google Scholar
• Lawrence T.S., Davis M.A. Selective radiosensitization and cytotoxicity of human melanoma cells using halogenated deoxycytidines and tetrahydrouridine. International Journal of Radiation Oncology, Biology, and Physics 1989; 16: 1243–1246
   PubMed Web of Science ®Google Scholar
• Lindstadt D., Blakely E., Phillips T.L., Castro J.R. Radiosensitization produced by iododeoxyuridine with high linear energy transfer heavy ion beams. International Journal of Radiation Oncology, Biology, and Physics 1988; 15: 703–710
   PubMed Web of Science ®Google Scholar
• Miller R.W., Degraff W., Kinsella T.J., Mitchell J.B. Evaluation of incorporated iododeoxyuridine cellular radiosensitization by photon activation therapy. International Journal of Radiation Oncology, Biology, and Physics 1987; 13: 1193–1197
   PubMed Web of Science ®Google Scholar
• Mitchell J.B., Kinsella T.J., Russo A., McPherson S., Rowland J., Smith B.H., Kornblith P.L., Glatstein E. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR). International Journal of Radiation Oncology, Biology, and Physics 1983; 9: 457–463
   PubMed Web of Science ®Google Scholar
• Mitchell J.B., Morstyn G., Russo A., Kinsella T.J., Fornace A.J., McPherson S., Glatstein E. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR. International Journal of Radiation Oncology, Biology, and Physics 1984; 10: 1447–1451
   PubMed Web of Science ®Google Scholar
• Mitchell J.B., Russo A., Kinsella T.J., Glatstein E. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy. International Journal of Radiation Oncology, Biology, and Physics 1986; 12: 1513–1518
   PubMed Web of Science ®Google Scholar
• Nath, R., Bongiorni, P., Rockwell, S. Enhanced IUdR radiosensitization by Am-241 photons relative to Ra-226 and I-125 at 0·72 Gy/hr. International Journal of Radiation Oncology, Biology, and Physics, in press, 1989
   Web of Science ®Google Scholar
• Perez L.M., Mekras J.A., Briggle T.V., Greer S. Marked radiosensitization of cells in culture to x-ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis. International Journal of Radiation Oncology, Biology, and Physics 1984; 10: 1453–1458
   PubMed Web of Science ®Google Scholar
• Phillips T.L., Bodell W.J., Uhl V., Ross G.Y., Rasmussen J., Mitchell J.B. Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. International Journal of Radiation Oncology, Biology, and Physics 1989; 16: 1251–1255
   PubMed Web of Science ®Google Scholar
• Russell K.J., Rice G.C., Brown J.M. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine. Cancer Research 1986; 46: 2883–2887
   PubMed Web of Science ®Google Scholar
• Russo A., Gianni L., Kinsella T.J., Klecker R.W.J., Jenkins J., Rowland J., Glatstein E., Mitchell J.B., Collins J., Myers C. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Research 1984; 44: 1702–1705
   PubMed Web of Science ®Google Scholar
• Schulte-Frohlinde D. Kinetics and mechanism of polynucleotide and DNA strand break formation. Radioprotectors and Anticarcinogens, O.R. Nygaard, M.G. Simic. Academic Press, New York 1983; 53–71, In
   Google Scholar
• Speth P.A.J., Kinsella T.J., Belanger K., Klecker R.W., Smith R., Rowland J.B., Collins J.M. Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: A phase I and clinical pharmacological study. Cancer Research. 1988; 48: 2933–2937
   Google Scholar
• Szybalski W. X-ray sensitization by halopyrimidines. Cancer Chemotherapy Reports 1974; 58: 539–557
   PubMedGoogle Scholar
• Tochner Z., Kinsella T.J., Rowland J., Glatstein E. Treatment of unresectable sarcomas of adults with hyperfractionated irradiation and iododeoxyuridine. Scientific Basis of Modern Radiotherapy, N.J. McNally. BIR Report 19, British Institute of Radiology, London 1989; 107–111, In
   Google Scholar
• Wollner I.S., Knutsen C.A., Ullrich K.A., Chrisp C.E., Juni J.E., Andrews J.C., Tuscan M.J., Stetson P.L., Ensminger W.D. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Research 1987; 47: 3285–3290
   PubMed Web of Science ®Google Scholar